Antiemetic Efficacy of Dexamethasone: Randomized, Double-Blind, Crossover Study with Prochlorperazine in Patients Receiving Cancer Chemotherapy

Maurie Markman, Vivian Sheidler, David S. Ettinger, Shirley A. Quaskey, E. David Mellits

Research output: Contribution to journalArticle

Abstract

We conducted a randomized, double-blind, crossover study comparing the antiemetic efficacy of dexamethasone and prochlorperazine in 42 patients with cancer who were receiving outpatient chemotherapy, mainly without cisplatin. Patients experienced significantly less nausea and vomiting with dexamethasone than with prochlorperazine (P<0.02 and <0.03, respectively). Twenty-five patients experienced no nausea with dexamethasone, as compared with 14 patients taking prochlorperazine (P<0.001). Similarly, 29 patients receiving dexamethasone did not vomit, as compared with 18 receiving prochlorperazine (P<0.001). Somnolence was the most frequent side effect, occurring in 60 per cent of patients receiving prochlorperazine and in 12 per cent of those receiving dexamethasone (P<0.001). Patients also experienced less suppression of appetite while receiving dexamethasone (P<0.02). We conclude that dexamethasone is an effective and safe antiemetic in patients receiving cancer chemotherapy without cisplatin. (N Engl J Med 1984; 311:549–52.).

Original languageEnglish (US)
Pages (from-to)549-552
Number of pages4
JournalNew England Journal of Medicine
Volume311
Issue number9
DOIs
StatePublished - Aug 30 1984

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antiemetic Efficacy of Dexamethasone: Randomized, Double-Blind, Crossover Study with Prochlorperazine in Patients Receiving Cancer Chemotherapy'. Together they form a unique fingerprint.

  • Cite this